Date: April 16, 2020

Journal: Integrative Cancer Therapies , Doi:

2020 | Evaluation of the Efficacy and Safety of the Herbal Formula PM014 in a Cisplatin- and Paclitaxel-Treated Tumor-Bearing Mouse Model…

Chanju Lee, PhD1, Hyunju Jeong, MS1, Kwang Hyung Lee, KMD1, Sehyun Park, KMD1, Mi Jung Gang, KMD1, Soo Kyung Bae, PhD2, and Hyunsu Bae, KMD, PhD1


PM014 (HL301) is a standardized herbal mixture derived from a traditional Korean medicine, Chung-Sang-Bo-Ha-Tang.
Previously, we reported that PM014 treatment significantly suppressed pulmonary fibrosis, one of the frequent adverse effects of anticancer therapy in lung cancer. Before the clinical application of PM014 in anticancer therapy, the safety and efficacy of PM014 in combination with conventional anticancer drugs should be addressed to determine whether PM014 can be used in lung cancer. Lewis lung cancer–bearing mice were injected with 10 mg/kg of cisplatin or paclitaxel on day 5. Starting on day 7, the mice were administered 200 mg/kg PM014 every 2 days. On day 15, all mice were
assessed by biochemical and histological analyses. PM014 did not block the antitumor activity of cisplatin and paclitaxel.
Coadministration of PM014 and antitumor agents did not elevate the aspartate transaminase/alanine transaminase ratio or the blood urea nitrogen/creatinine ratio. Histopathological analysis also showed that PM014 did not induce hepatic or renal injury. Moreover, PM014 had no apparent inhibitory effects on drug metabolizing enzymes, indicating that PM014 did not alter the pharmacokinetics of chemotherapeutic drugs. Overall, these data show the safety and compatibility of combination therapy of PM014 and chemotherapies for the treatment of lung cancer.
  • 페이스북으로 보내기
  • 트위터로 보내기
  • 미투데이로 보내기
  • 구글플러스로 보내기